Abstract: Herein is disclosed synthetic oligonucleotides comprising 2?F-ANA nucleosides that can be utilized to control plant-chewing and phloem-feeding insects, bacteria present in such insects, and bacteria present in plants. The novel approaches and materials provided herein allow for reduction of pesticide and antibiotic use without the need to create genetically modified plants.
Type:
Grant
Filed:
January 5, 2022
Date of Patent:
April 2, 2024
Assignees:
The United States of America, as represented by the Secretary of Agriculture, AUM LifeTech, Inc.
Abstract: Herein is disclosed synthetic oligonucleotides comprising 2?F-ANA nucleosides that can be utilized to control plant-chewing and phloem-feeding insects, bacteria present in such insects, and bacteria present in plants. The novel approaches and materials provided herein allow for reduction of pesticide and antibiotic use without the need to create genetically modified plants.
Type:
Grant
Filed:
July 3, 2019
Date of Patent:
February 22, 2022
Assignees:
The United States of America, as represented by The Secretary of Agriculture, AUM Lifetech, Inc.
Abstract: Modulation of microRNAs against myotonic dystrophy type 1 and antagonists of microRNAs therefor. The invention provides the use of inhibitors of microRNAs repressors of MBNL1 and/or MBNL2 genes for the manufacture of a medicinal product for the treatment of myotonic dystrophy 1. Inhibiting these microRNAs allows to increase the endogenous levels of the corresponding proteins MBNL1 and/or MBNL2, thereby alleviating symptoms of the disease, especially when inhibiting repressors that are expressed in the main affected organs: skeletal muscle, heart or organs of the central nervous system. The inhibition of the microRNAs miR-23b-3p and miR-218-5p is preferred. It also provides oligoribonucleotide or oligoribonucleotide analogue antagonists suitable therefor, preferably antagomiRs directed against the microRNAs mentioned with chemical modifications that enhance their interaction with the target, their stability in vivo and their ability to penetrate into the cells and distribute throughout tissues and organs.
Type:
Grant
Filed:
September 19, 2017
Date of Patent:
December 21, 2021
Assignees:
UNIVERSITAT DE VALENCIA, AUM LIFETECH, INC.
Inventors:
Rubén D. Artero Allepuz, María Beatriz LlamusíTroisi, Estefanía Cerro Herreros, Juan M. Fernández Costa, Veenu Aishwarya, Thorleif Møller
Abstract: The invention relates to compositions and methods for enhancing or upregulating utrophin protein production and methods for treating myopathies, such as Duchenne Muscular Dystrophy (DMD). Specifically, the invention relates to compositions, such as oligonucleotides, and methods for enhancing or upregulating utrophin in a subject by blocking binding of let-7c miRNA to the utrophin mRNA 3 untranslated region (UTR).
Type:
Application
Filed:
March 18, 2019
Publication date:
February 11, 2021
Applicants:
THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA, AUM LifeTech, Inc
Inventors:
Tejvir S. KHURANA, MANOJ KUMAR MISHRA, Veenu AISHWARYA